Clinical trials: Diffuse Parenchymal Lung Diseases
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
- Trial name
- NCT00076635
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- InterMune
Interstitial Lung Disease
Stylet vs No Stylet During EBUS TBNA
This research study compares two ways to biopsy lymph nodes in the chest using endobronchial ultrasound-guided transbronchial needle aspiration" (EBUS-TNBA).
- Trial name
- NCT02201654
- Testing
- EBUS without stylet
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Johns Hopkins University
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.
- Trial name
- PHiano (NCT01265888)
- Testing
- Inhaled Nitric Oxide
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Geno LLC
Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Mechanisms of Familial Pulmonary Fibrosis
This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP).
- Conditions
- Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Familial Interstitial Pneumonia
- Trial name
- NCT03437486
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Vanderbilt University Medical Center
Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic
BPF Genetics of ILD Study
The investigators aim to examine the genetic determinants of interstitial lung disease in a cohort of subjects with regular exposure to pigeons, a known cause of one form of interstitial lung disease known as hypersensitivity…
- Conditions
- Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic, Bird Fancier's Lung, Idiopathic Interstitial Pneumonias
- Trial name
- BPF GILD (NCT03747627)
- Testing
- Genetic profiling
- Where
- 2 sites in United Kingdom
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Idiopathic Pulmonary Fibrosis
Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis.
- Trial name
- BUILD 1 (NCT00071461)
- Testing
- bosentan
- Where
- 29 sites in United States, Canada and 6 more
- Volunteers
- 158 people
- Sponsor
- Actelion
Idiopathic Pulmonary Fibrosis(IPF)
Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui…
- Trial name
- NCT06914713
- Testing
- Jin-shui Huan-xian granule
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.
- Conditions
- Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE), Connective Tissue Disease-associated Interstitial Lung Disease
- Trial name
- Cell therapy (NCT07490041)
- Testing
- KN5601
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Interstitial Lung Disease (ILD)
Nasal High-flow Oxygen Therapy During Rehabilitive Exercise Training in ILD
Although uncommon, interstitial lung diseases (ILDs), and particularly idiopathic pulmonary fibrosis (IPF), are progressive, irreversible, and ultimately fatal without treatment.
- Trial name
- PID-OX (NCT07679854)
- Testing
- Pulmonary rehabilitation with NHFO2, Pulmonary rehabiltation with conventional oxygen therapy
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Frédéric Hérengt
Interstitial Lung Disease, Interstitial Pulmonary Fibrosis
Enhancing Physical Activity in Patients With Interstitial Lung Disease
The level of physical activity (PA) has been shown to be an important predictor for morbidity and mortality in patients with chronic respiratory diseases such as COPD and more recently Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT04138173
- Testing
- Tele coaching intervention
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- KU Leuven
COPD Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Assessing Functional Capacity in Directly and Remotely Monitored Home-based Settings: A Protocol for a Multinational Validation Study in Individuals With Chronic Respiratory Diseases
The goal of this validation study is to provide further evidence of the metrological properties of the 6-minute stepper test in individuals with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
- Trial name
- 6MST (NCT06447831)
- Where
- 3 sites in Canada, France
- Volunteers
- 89 people
- Sponsor
- Laval University
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Toward Self-management in ILD
Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Connective Tissue Related ILD, Chronic Hypersensitivity Pneumonitis
- Trial name
- NCT03300583
- Testing
- Focus groups, Semi-structured interviews
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kingston University
Idiopathic Pulmonary Fibrosis
A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids.
- Trial name
- NCT00047645
- Testing
- Interferon-gamma 1b
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- InterMune
Fibrotic Interstitial Lung Disease
Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease
Our study aims to investigate the benefits of an outpatient pulmonary rehabilitation program in a population of subjects with fibrotic interstitial lung disease.
- Trial name
- NCT00415272
- Testing
- Pulmonary Rehabilitation
- Where
- United States
- Sponsor
- University of California, San Francisco
Pulmonary Fibrosis
Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients
Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what research attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05899556
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Hiatal Hernia, Interstitial Lung Disease
Hiatal Hernia and Pulmonary Involvement
Patients often present with a significant burden of fibrosis upon diagnosis as there is interest in identifying these individuals earlier in their disease course (i.e., "subclinical disease") where targeted treatments and…
- Trial name
- NCT05716022
- Testing
- Blood Collection, Bronchoscopy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Virginia
Chronic Pulmonary Disease
Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study
Chronic pulmonary disease like interstitial lung disease (ILD) and chronic obstructive lung disease (COPD) are a significant health problem in Canada and around the world.
- Trial name
- Tele-RehaB (NCT04658979)
- Testing
- Pulmonary tele-rehabilitation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Radiation Pneumonitis
The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia
Radiation pneumonitis (RP) is a common complication of radiotherapy for thoracic tumors, and the incidence rate of grade 2 or above RP is 20% -40%; The use of antibiotics after secondary bacterial infection due to radiation…
- Trial name
- NCT06079931
- Testing
- Babaodan Capsule
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement
Progressive SSc is an entity with limited therapeutic alternatives and with asurvival rate of less than 45% in the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT04432545
- Testing
- Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
- Where
- Colombia
- Sponsor
- Universidad de la Sabana
Systemic Sclerosis With and Without Interstitial Lung Disease
A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.
- Trial name
- NCT04948554
- Testing
- MK-2225
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 5 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.